Sachem Capital Corp. 8.00% Notes due 2027 (SCCG)
Live price chart, market sentiment, and community perspectives for Sachem Capital Corp. 8.00% Notes due 2027 (AMEX: SCCG).
Live price chart, market sentiment, and community perspectives for Sachem Capital Corp. 8.00% Notes due 2027 (AMEX: SCCG).
On our desk, the contrast between the equity-level fundamentals and the fixed-income reaction is stark. Sachem Capital Corp. reported a Q1 2026 EPS of -$0.15 against an estimate of $0.0051—a staggering -3,041.18% miss—yet the 8.00% Notes due 2027 (SCCG) barely blinked, moving only marginally. It highlights how fixed-income holders often look strictly at the coupon structure rather than transient bottom-line shocks.
Watching the tape on SCCG following the Q2 2026 earnings release, I noticed an EPS slide to -$0.14, missing consensus by over 1,015%. Remarkably, the notes still edged up by 0.53. Market sentiment here suggests that bad news may have already been heavily priced in, or participants are prioritizing yield over immediate issuer headwinds.
Our risk management team flagged the complete lack of disclosed revenue data alongside the abysmal Q1 and Q2 2026 net losses. While the notes have shown resilience—edging up or moving sideways after severe earnings misses—elevated downside risks remain if long-term support signals fail to hold.
When evaluating fixed-income instruments like the Sachem Capital 8.00% Notes due 2027, pay close attention to technical support and resistance levels. Recent analytics place support around $23.33 and resistance near $25.79, with current trading hovering near $24.56. Tactical traders must weigh these boundaries carefully against the backdrop of undisclosed revenue data.
As a credit analyst reviewing the Indenture terms dating back to June 2019 and the August 2022 Seventh Supplemental Indenture, the structural covenants of the 8.0% notes maturing September 30, 2027, remain paramount. Despite consecutive multi-thousand-percent EPS surprises on the negative side, the legal framework of the notes provides the primary anchor for institutional holders.
Explore plasma cleansing, somatic organ swaps, and BCI.